$ACGL

ETF Activity: QQQ Outflows Offset SPY Inflows on Friday

On Friday, ETFs saw net outflows of $2.05 billion. SPY had inflows of $3.47 billion, while QQQ had outflows of $3.33 billion and IGV saw $746.5 million in outflows. Arch Capital Group (ACGL) had the highest additions at $185.2 million, and Gilead Sciences (GILD) had the highest trims at -$200.9 million.

Original reporting
Published Oct 20, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ETF Activity: QQQ Outflows Offset SPY Inflows on Friday — source image
Decision brief

The 30-second read

$ACGLBullishLow
01

Why it matters

The article provides fresh, estimated fund flow numbers for the day, offering short‑term trading signals for the listed stocks.

02

Market read

ETF flow data can influence short‑term price direction for the highlighted stocks but lacks broader macro significance.

03

What to watch

The reported flows are estimates and may not reflect actual trading activity; underlying earnings or news could dominate price moves.

Relevance 4/10Novelty 2/10Timing: today

Background

Daily ETF flow report summarizing net inflows and outflows for major ETFs and the top individual stocks impacted.

Company-level read

Ticker impact

$ACGLBullishMedium confidence
Context

ETFs added $185.2 million of Arch Capital Group shares on Friday.

Expected impact

likely upward pressure as ETFs accumulate shares

Evidence & confidence

ETF buying indicates demand and may lift price in the short term.

$PSXBullishMedium confidence
Context

ETFs added $167.4 million of Phillips 66 shares on Friday.

Expected impact

potential modest upside from fund accumulation

Evidence & confidence

Large fund inflow often translates into near‑term buying pressure.

$ECLBullishMedium confidence
Context

ETFs added $160.2 million of Ecolab shares on Friday.

Expected impact

likely upward bias as funds increase holdings

Evidence & confidence

Fund inflows are a bullish signal for the stock.

$GILDBearishMedium confidence
Context

ETFs trimmed $200.9 million of Gilead Sciences shares on Friday.

Expected impact

likely downward pressure as funds reduce exposure

Evidence & confidence

Significant fund outflow can weigh on the stock in the short term.

$RMDBearishMedium confidence
Context

ETFs trimmed $198.0 million of ResMed shares on Friday.

Expected impact

likely downward pressure from fund selling

Evidence & confidence

Large fund exits often translate into near‑term price weakness.

$ABNBBearishMedium confidence
Context

ETFs trimmed $192.5 million of Airbnb shares on Friday.

Expected impact

likely pressure as funds cut positions

Evidence & confidence

Fund outflows are a bearish indicator for the stock.

Market effects

ETF flow data highlights sector rotation preferences but does not signal a broad sector shift.

U.S. equity market sentiment may be modestly affected by the net outflow of $2.05 bn across ETFs.

Limited to U.S. investors; no direct global macro impact.

Counterpoint

Fund outflows could be temporary and present buying opportunities for contrarian investors.

Key entities

  • Arch Capital Group

    Top stock added by ETFs on the day.

  • Gilead Sciences

    Top stock trimmed by ETFs on the day.

Related articles

$GILDMedAI 8/10

BofA raises Gilead Sciences stock price target on positive trial data

BofA Securities raised Gilead Sciences' (GILD) price target to $172 from $168, citing positive phase 2 trial data for emvistegrast. The stock trades at $153.07, up 27% year-over-year. Gilead also reported better-than-expected Q2 2026 results, with revenue of $7.8B. BofA maintains a Buy rating. Gilead is involved in collaborations with Assembly Biosciences and MacroGenics.

$GILDMed

Gilead’s UC Pill Hits Trial Goal, Stock Still Slips

Gilead Sciences (GILD) reported that its experimental ulcerative colitis pill, emvistegrast, met the main goal in a mid-stage trial, with 66% of patients achieving clinical response. Shares fell 1.42% to $153.555 on 19 October 2026. The company posted a net loss of $10,496m in Q2 2026, reversing from a profit in Q1. The trial data was presented at a European gastroenterology meeting.

$PSXMed

Phillips 66 Stock Is Up 133%. Can Its Dividend Keep Growing?

Phillips 66 (PSX) raised its quarterly dividend to $1.33 per share, a 4.7% increase. The stock is up 133% year-to-date, with a forward yield of 1.8%. Q2 cash from operations was $4.317 billion, covering dividends. Midstream and marketing businesses fund the dividend, while debt paydown is a priority. The company expects stronger refining margins through 2027 but acknowledges volatility. Comparisons with Valero (VLO) and Marathon (MPC) were discussed.

$GILDMedAI 8/10

Gilead to present HIV and antiviral research at IDWeek 2026

Gilead Sciences (GILD) will present 28 research findings at IDWeek 2026, including data on Bixlenvo for HIV treatment, Yeztugo for HIV prevention, and GS-1179 for genital herpes. Studies cover treatment outcomes, real-world adoption, and Phase 1b results. Bixlenvo is U.S.-approved, Yeztugo has global approvals, and GS-1179 is investigational.

$GILDMed

Gilead will present early U.S. use data on a twice-yearly HIV prevention shot

Gilead Sciences will present data on its HIV treatments, including Bixlenvo and Biktarvy, at IDWeek 2026. The company will share findings from Phase 3 studies on Bixlenvo's safety and efficacy in patients with comorbidities and renal impairment. Additionally, Gilead will present real-world evidence on the adoption of lenacapavir for HIV prevention and Phase 1b data on GS-1179 for recurrent genital herpes.